Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
December 10 2007 - 6:30AM
PR Newswire (US)
THE WOODLANDS, Texas, Dec. 10 /PRNewswire-FirstCall/ -- Lexicon
Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that a member
of Lexicon senior management will participate in the RBC Capital
Markets Healthcare Conference panel Going With Your Gut: New
Treatments for GI Disorders at The Westin Times Square Hotel in New
York, New York on Wednesday, December 12, 2007 at 8:00 a.m. Eastern
Time. A live audio webcast of the panel presentation may be
accessed on Lexicon's corporate website at
http://www.lexpharma.com/. An archived version of the webcast will
be available on the website through December 20, 2007. About
Lexicon Lexicon is a biopharmaceutical company focused on the
discovery and development of breakthrough treatments for human
disease. Lexicon currently has clinical programs underway for such
areas of major unmet medical need as irritable bowel syndrome,
cognitive disorders, and rheumatoid arthritis. The company has used
its proprietary gene knockout technology to discover more than 100
promising drug targets and create an extensive pipeline of clinical
and preclinical programs in the therapeutic areas of diabetes and
obesity, cardiovascular disease, psychiatric and neurological
disorders, cancer, immune system disorders and ophthalmic disease.
To advance the development and commercialization of its programs,
Lexicon is working both independently and through collaborators
including Bristol-Myers Squibb Company, Genentech, Inc. and N.V.
Organon. For additional information about Lexicon and its programs,
please visit http://www.lexpharma.com/. Safe Harbor Statement This
press release contains "forward-looking statements," including
statements relating to Lexicon's growth and future operating
results, discovery and development of products, strategic alliances
and intellectual property, as well as other matters that are not
historical facts or information. All forward-looking statements are
based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors that may
cause Lexicon's actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under "Factors Affecting Forward-Looking Statements" and
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2006, as filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or revise
any such forward-looking statements, whether as a result of new
information, future events or otherwise. DATASOURCE: Lexicon
Pharmaceuticals, Inc. CONTACT: Bobbie Faulkner, Manager, Investor
and Public Relations, of Lexicon Pharmaceuticals, Inc.,
+1-281-863-3503, Web site: http://www.lexpharma.com/
Copyright
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024